vVARDIS Secures Additional Funding to Advance Curodont Expansion

September 11, 2025

Swiss dental innovator vVARDIS has recently obtained new financial backing to further the global adoption of its groundbreaking Curodont product. Building on OrbiMed’s earlier $35 million investment in February, this latest funding aims to enhance the company’s operational capabilities and broaden its reach within the dental industry. The initial capital facilitated the expansion of clinical and sales teams, strengthened distribution networks, and fostered deeper connections with dental professionals in strategic markets. This infusion of resources underscores vVARDIS’s commitment to revolutionizing dental care through innovative, patient-centric solutions.

Phases of Curodont’s Impact

Curodont represents a paradigm shift in the management of early carious lesions, offering a non-invasive alternative to traditional restorative techniques. Its unique biomimetic composition leverages the natural components of saliva, specifically calcium and phosphate ions, to stimulate enamel remineralization at sites of early decay. By eliminating the need for needles or drills, Curodont aligns with the principles of minimally invasive dentistry, preserving the integrity of natural tooth structure while streamlining clinical procedures.

Key Benefits for Clinicians and Patients

Preservation of Tooth Structure: Curodont’s non-invasive approach minimizes the removal of healthy enamel, maintaining long-term tooth integrity.

Efficiency in Practice: By reducing the need for invasive interventions, clinicians can optimize chair time, enhancing practice productivity.

Patient Comfort: The drill-free and needle-free treatment enhances patient experience, reducing anxiety and improving satisfaction.

Evidence-Based Outcomes: The biomimetic formulation promotes natural enamel regeneration, offering a scientifically validated solution for early caries management.

Strategic Growth and Industry Impact

Dr. Haleh and Dr. Golnar Abivardi, the visionary co-CEOs and founders of vVARDIS, expressed enthusiasm about the expanded collaboration with OrbiMed. “This additional investment, paired with OrbiMed’s industry expertise, empowers us to scale our mission of transforming dental care worldwide,” they stated. “As practicing dentists, we are deeply committed to advancing a non-invasive solution that elevates patient care standards and supports clinicians in delivering exceptional outcomes.”

Matthew Rizzo, a general partner at OrbiMed, highlighted the company’s rapid progress: “Since our initial investment, vVARDIS has demonstrated remarkable traction in the dental market with Curodont. The product’s growing adoption and the enthusiastic response from dental professionals have solidified our confidence in its potential. We are excited to deepen our partnership and support vVARDIS as it enters this next chapter of growth.”

Market Penetration and Achievements

vVARDIS has established itself as a leader in its category, achieving the status of the fastest-growing dental manufacturer. Since January 2024, Curodont has been used to treat over one million teeth in the United States, with nearly 10% of U.S. dental practices now incorporating the treatment. This adoption reflects its application in more than 400,000 patients, underscoring its widespread acceptance and clinical efficacy.

Conclusion

The latest investment in vVARDIS marks a significant milestone in its mission to redefine dental care through Curodont. By combining cutting-edge biomimetic technology with strategic financial and operational support, vVARDIS is poised to expand its global footprint, empowering dental professionals and enhancing patient outcomes. As the company continues to innovate, it sets a new benchmark for minimally invasive dentistry, offering a future where early caries management is both effective and patient-friendly.

Comments